** Shares of drug developer Generation Bio GBIO.O rise 30% to $5.28 premarket
** Late on Tuesday co said it is exploring strategic alternatives, including a sale, merger, or asset deal, with TD Cowen advising
** Co also restructuring with about a 90% workforce reduction by end of October
** Co posted Q2 sales of $765,000, well below analysts' est of $3.1 mln - LSEG
** Co reported Q2 loss per share of $3.12, compared to estimate loss of 2.85/share - LSEG
** Co also said its experimental drug delivery system successfully targeted immune cells in monkey studies for the first time and showed promise for treating autoimmune diseases by blocking key immune cell proteins
** As of last close, stock down 61% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.